Research and Trials
Please read below about research opportunities and new targeted treatment medications:
VACOM: A study on Communications in Vascular Anomalies
Dr. Bryan Sisk and Dr. Anna Kerr at Washington University in St. Louis are conducting a Vascular Anomalies Communications (VACOM) Study and are seeking participants with FAVA and other vascular anomalies. Phase II of this study is open to adult patients and caregivers over the age of 18. Residents of all countries are encouraged to participate. The total time commitment is one 20-30 minute survey. U.S. participants receive a $25 Amazon gift card for their time.
The findings from this research will be essential to develop future interventions to improve medical care and communication for families who experience barriers in dealing with their and their loved one's FAVA and other vascular anomalies. Contact Dr. Bryan Sisk with any questions at siskb@wustl.edu.
Please register today using this link: VACOM Study
Novartis Pharmaceuticals is sponsoring a study to understand the health-related quality of life of patients with FAVA and other PROS conditions. The total time commitment is one 30-minute survey. Participants receive $60 for their time.
The study is open to:
-
Adults (age 18+) who have been diagnosed by a doctor with FAVA or other PROS condition
-
Children (ages 12-17) who have been diagnosed by a doctor with FAVA or other PROS condition
-
Parents/legal guardians of children (ages 5-11) diagnosed by a doctor with FAVA or other PROS condition
-
Parents/legal guardians of children (ages 12-17) diagnosed by a doctor with FAVA or other PROS condition who may not be able to complete the survey on their own
Open to U.S. Residents only.
If you would like to participate or have questions, please contact Global Perspectives at contact@global-patients.com or (518)768-7995.
In May, 2019, the FDA approved a PI3K inhibitor manufactured by Novartis Pharmaceuticals for the treatment of breast cancer. The drug, Piqray (AKA alpelisib and BYL719), is the first FDA-approved PI3K inhibitor on the market specifically targeting patients with a PIK3CA mutation.
Now, Novartis is sponsoring a prospective Phase II multi-center study with an upfront 16-week, randomized, double-blind, placebo-controlled period, and extension periods, to assess the efficacy, safety and pharmacokinetics of alpelisib in eligible pediatric and adult participants with conditions within the PROS (PIK3CA-related overgrowth spectrum) umbrella, including FAVA. Enrollment is currently open in various locations in the United States and Europe.
Please use this link to learn more: Alpelisib Study
Registry for COVID-19 in the Vascular Anomaly Population
If you have a vascular anomaly and contract COVID-19, please ask your doctor to complete the brief questionnaire below.
Surveillance Epidemiology of Coronavirus (COVID-19) Under Research Exclusion for Vascular Anomalies
Researchers need information on COVID-19 and vascular anomalies.
The SECURE-VA registry is a collaborative worldwide registry for healthcare providers to report COVID-19 in vascular anomaly patients. We hope to quickly characterize the impact of COVID-19 on people with vascular anomalies.
The study is anonymous and meets exemption criteria under federal regulations. Complete information on security and online collection can be found here.
If you have a vascular anomaly and you contract COVID-19, please provide the link below to your doctor. The form is quick to complete:
https://www.research.chop.edu/secure-va
Patient registries provide researchers with the opportunity to analyze anonymous data that is generated and collected over a specific time. The true analytical value of registries can only be achieved when sufficient numbers of participants provide access to their data.
Photo courtesy of Sippakorn Yamkasikorn on Unsplash